MRZ 2-514 is primarily investigated for its potential therapeutic applications in neurological and psychiatric disorders. It acts as a selective antagonist for certain glutamate receptors, particularly those involved in excitatory neurotransmission. This makes it a candidate for treating conditions like epilepsy, where excessive glutamate activity can lead to neuronal damage. Additionally, its neuroprotective properties are being explored in the context of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Research also suggests its utility in managing chronic pain and anxiety disorders, as it modulates pathways associated with these conditions. However, its clinical use is still under investigation, with studies focusing on efficacy, safety, and optimal dosing.